JPMorgan Chase & Co. reaffirmed their neutral rating on shares of GlaxoSmithKline plc (LON:GSK) in a report released on Tuesday morning. They currently have a GBX 1,670 ($21.02) price target on the stock.
A number of other analysts have also recently issued reports on GSK. Deutsche Bank AG reissued a hold rating and set a GBX 1,720 ($21.65) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, April 12th. BNP Paribas reissued an underperform rating and set a GBX 1,520 ($19.13) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, December 21st. Barclays PLC reissued an equal weight rating and set a GBX 1,550 ($19.51) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, April 12th. Shore Capital reissued a hold rating on shares of GlaxoSmithKline plc in a research note on Thursday, March 30th. Finally, Liberum Capital reaffirmed a buy rating and set a GBX 1,900 ($23.91) price target on shares of GlaxoSmithKline plc in a research note on Thursday, January 19th. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the company. GlaxoSmithKline plc has a consensus rating of Hold and a consensus target price of GBX 1,739.27 ($21.89).
GlaxoSmithKline plc (LON:GSK) opened at 1562.50 on Tuesday. The firm’s market cap is GBX 76.05 billion. The stock has a 50 day moving average of GBX 1,660.68 and a 200 day moving average of GBX 1,595.67. GlaxoSmithKline plc has a 52 week low of GBX 1,363.00 and a 52 week high of GBX 1,745.56.
ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Earns “Neutral” Rating from JPMorgan Chase & Co.” was reported by Mideast Time and is owned by of Mideast Time. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.mideasttime.com/glaxosmithkline-plc-gsk-earns-neutral-rating-from-jpmorgan-chase-co/1624467.html.
The firm also recently declared a dividend, which was paid on Thursday, April 13th. Shareholders of record on Thursday, February 23rd were issued a dividend of GBX 23 ($0.29) per share. This is an increase from GlaxoSmithKline plc’s previous dividend of $19.00. The ex-dividend date was Thursday, February 23rd. This represents a yield of 1.47%.
In other GlaxoSmithKline plc news, insider Dominic Redfern purchased 230 shares of the business’s stock in a transaction on Thursday, April 13th. The stock was acquired at an average price of GBX 1,639 ($20.63) per share, with a total value of £3,769.70 ($4,744.75). Also, insider Vivienne Cox purchased 342 shares of the business’s stock in a transaction on Wednesday, February 8th. The shares were acquired at an average cost of GBX 1,555 ($19.57) per share, with a total value of £5,318.10 ($6,693.64). In the last ninety days, insiders have acquired 718 shares of company stock valued at $1,173,224 and have sold 52,038 shares valued at $84,442,106.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.